Literature DB >> 20127048

Daedalea gibbosa substances inhibit LPS-induced expression of iNOS by suppression of NF-kappaB and MAPK activities in RAW 264.7 macrophage cells.

Nili Ruimi1, Haithem Rwashdeh, Solomon Wasser, Badireenath Konkimalla, Thomas Efferth, Monica Borgatti, Roberto Gambari, Jamal Mahajna.   

Abstract

Nitric oxide (NO) is a radical molecule produced by iNOS and plays a role in various physiological and pathophysiological conditions including inflammatory diseases and cancer. In the present study, organic extract of Daedalea gibbosa was effective in inhibiting NO and PGE2 production in RAW 264.7 cells. The extract of D. gibbosa was chemically fractionated leading to the isolation of three active fractions (F5-F7) that were effective in inhibiting NO and iNOS production. In addition, F6 and F7 significantly inhibited the iNOS transcript, while F5 did not cause a reduction in the iNOS transcript. Furthermore, the active fractions showed a differential effect on levels of phospho-p38, phospho-JNK, and phospho-IKBalpha. Phopsho-p38 was moderately inhibited by F5 and only F7 was significantly active in inhibiting phospho-IKBalpha. Interestingly, all active fractions significantly enhanced levels of phospho-JNK. In addition, the three active fractions also showed differential inhibitory effects on NF-kappaB DNA binding activity.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20127048     DOI: 10.3892/ijmm_00000361

Source DB:  PubMed          Journal:  Int J Mol Med        ISSN: 1107-3756            Impact factor:   4.101


  8 in total

1.  Stevioside suppressed inflammatory cytokine secretion by downregulation of NF-κB and MAPK signaling pathways in LPS-stimulated RAW264.7 cells.

Authors:  Li Fengyang; Fu Yunhe; Liu Bo; Liu Zhicheng; Li Depeng; Liang Dejie; Zhang Wen; Cao Yongguo; Zhang Naisheng; Zhang Xichen; Yang Zhengtao
Journal:  Inflammation       Date:  2012-10       Impact factor: 4.092

2.  Platinum (IV)-fatty acid conjugates overcome inherently and acquired Cisplatin resistant cancer cell lines: an in-vitro study.

Authors:  Einav Ratzon; Yousef Najajreh; Rami Salem; Hazem Khamaisie; Martin Ruthardt; Jamal Mahajna
Journal:  BMC Cancer       Date:  2016-02-23       Impact factor: 4.430

3.  Punicalagin protects bovine endometrial epithelial cells against lipopolysaccharide-induced inflammatory injury.

Authors:  An Lyu; Jia-Jia Chen; Hui-Chuan Wang; Xiao-Hong Yu; Zhi-Cong Zhang; Ping Gong; Lin-Shu Jiang; Feng-Hua Liu
Journal:  J Zhejiang Univ Sci B       Date:  2017-06       Impact factor: 3.066

4.  Inhibition of TNFα-induced iNOS expression in HSV-tk transduced 9L glioblastoma cell lines by Marasmius oreades substances through NF-κB- and MAPK-dependent mechanisms.

Authors:  Nili Ruimi; Roumyana D Petrova; Riad Agbaria; Sherbel Sussan; Solomon P Wasser; Abraham Z Reznick; Jamal Mahajna
Journal:  Mol Biol Rep       Date:  2010-03-12       Impact factor: 2.316

5.  Safety of herbal medicine use during chemotherapy in patients with ovarian cancer: a "bedside-to-bench" approach.

Authors:  Eran Ben-Arye; Ofer Lavie; Noah Samuels; Hazem Khamaisie; Elad Schiff; Orit Gressel Raz; Jamal Mahajna
Journal:  Med Oncol       Date:  2017-02-25       Impact factor: 3.064

6.  Adventitious root cultures of Oplopanax elatus inhibit LPS-induced inflammation via suppressing MAPK and NF-κB signaling pathways.

Authors:  Wen Tian; Xuan-Mei Piao; Cheng-Ri Yin; Xiao-Long Jiang; Hao-Ding Sun; Xiao-Li An; Jun Jiang; Mei-Lan Lian
Journal:  In Vitro Cell Dev Biol Anim       Date:  2019-09-16       Impact factor: 2.416

Review 7.  DNA Microarray-Based Screening and  Characterization of Traditional Chinese Medicine.

Authors:  Ryoiti Kiyama
Journal:  Microarrays (Basel)       Date:  2017-01-30

8.  Exopolysaccharide from Paecilomyces lilacinus modulates macrophage activities through the TLR4/NF‑κB/MAPK pathway.

Authors:  Chao He; Hai-Yan Lin; Cai-Chun Wang; Ming Zhang; Ying-Ying Lin; Feng-Ying Huang; Ying-Zi Lin; Guang-Hong Tan
Journal:  Mol Med Rep       Date:  2019-10-15       Impact factor: 2.952

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.